Medicure Reports Financial Results for Quarter Ended June 30, 2024

Medicure Inc. has reported its financial results for the quarter ended June 30, 2024. The company recorded a total net revenue of $5.2 million, down from $6.0 million in the same period in 2023.

AGGRASTAT® generated $1.8 million during the quarter, a decrease from last year's $2.6 million. Revenue from Marley Drug remained stable at $2.7 million, with ZYPITAMAG® sales increasing to $790,000.

Adjusted EBITDA for Q2 2024 was negative $514,000 compared to positive $948,000 in Q2 2023. The net loss for the quarter was $1.2 million, an unfavorable shift from the net income of $253,000 recorded in the previous year.

The company's unrestricted cash decreased to $5.9 million from $6.4 million as of December 2023. Operating activities used $162,000 in cash during the first half of 2024.